Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soichiro Shibui

Showing results (51-60 of 92) with videos related to

Pageof 10
Sort By:
Brain Tumor Pathology|April 22, 2014
Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomasHideyuki Arita, Yoshitaka Narita, Yuko Matsushita, et al.
Brain Tumor Pathology|February 16, 2017
Erratum to: Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomasHideyuki Arita, Yoshitaka Narita, Yuko Matsushita, et al.
Stem Cell Research|May 9, 2013
Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cellsAtsushi Sato, Masashi Okada, Keita Shibuya, et al.
Cancer|November 26, 2009
Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancerKan Yonemori, Koji Tsuta, Makiko Ono, et al.
Brain Tumor Pathology|July 14, 2012
Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation statusMakoto Ohno, Yoshitaka Narita, Yasuji Miyakita, et al.
International Journal of Oncology|July 25, 2012
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapyYoshiko Okita, Yoshitaka Narita, Yasuji Miyakita, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|March 8, 2012
A case of unclassified high-grade glioma with polar spongioblastoma patternShintaro Fukushima, Yoshitaka Narita, Aya Shinomiya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiformeMizuhiko Terasaki, Soichiro Shibui, Yoshitaka Narita, et al.
International Journal of Computer Assisted Radiology and Surgery|February 6, 2014
Usefulness of a glass-free medical three-dimensional autostereoscopic display in neurosurgeryYoshitaka Narita, Shinsuke Tsukagoshi, Masahiro Suzuki, et al.
Stem Cells Translational Medicine|December 1, 2012
Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPKAtsushi Sato, Jun Sunayama, Masashi Okada, et al.
Pageof 10

Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Brain Tumor Pathology|April 22, 2014
Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomasHideyuki Arita, Yoshitaka Narita, Yuko Matsushita, et al.
Brain Tumor Pathology|February 16, 2017
Erratum to: Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomasHideyuki Arita, Yoshitaka Narita, Yuko Matsushita, et al.
Stem Cell Research|May 9, 2013
Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cellsAtsushi Sato, Masashi Okada, Keita Shibuya, et al.
Cancer|November 26, 2009
Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancerKan Yonemori, Koji Tsuta, Makiko Ono, et al.
Brain Tumor Pathology|July 14, 2012
Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation statusMakoto Ohno, Yoshitaka Narita, Yasuji Miyakita, et al.
International Journal of Oncology|July 25, 2012
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapyYoshiko Okita, Yoshitaka Narita, Yasuji Miyakita, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|March 8, 2012
A case of unclassified high-grade glioma with polar spongioblastoma patternShintaro Fukushima, Yoshitaka Narita, Aya Shinomiya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiformeMizuhiko Terasaki, Soichiro Shibui, Yoshitaka Narita, et al.
International Journal of Computer Assisted Radiology and Surgery|February 6, 2014
Usefulness of a glass-free medical three-dimensional autostereoscopic display in neurosurgeryYoshitaka Narita, Shinsuke Tsukagoshi, Masahiro Suzuki, et al.
Stem Cells Translational Medicine|December 1, 2012
Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPKAtsushi Sato, Jun Sunayama, Masashi Okada, et al.
Pageof 10